Rare Kidney Diseases Market

Rare Kidney Diseases Market by Target Indications (IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy and Others), Type of Molecule, Route of Administration and Key Geographies: Industry Trends and Global Forecast, 2022-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    98

  • Slides
    196

  • View Count
    8750

Rare Kidney Diseases Market Overview

The rare kidney diseases market is expected to grow at a CAGR of 15% during the forecast period. It is worth highlighting that the prevalence rate of rare kidney disorders (RKD), including IgA nephropathy, lupus nephritis, focal segmental glomerular sclerosis, membranous nephropathy and C3 glomerulopathy, is estimated to be 60-80 per 100,000 cases / individuals in the US and Europe. Despite their relatively low prevalence, these set of indications are believed to be one of the leading causes of renal diseases, along with diabetes and other rare genetic kidney disorders. The low disease incidence rate of such disorders, coupled to the lack of awareness among the general population, often leads to late or erroneous diagnosis. This, in turn, enables suboptimal therapeutic management, as well as compromised long-term outcomes. The aforementioned factors are some of the key reasons that are believed to be responsible for high mortality rates and severe compromise on chance of survival of a patient suffering with rare kidney disorders. It is worth mentioning that, post the onset of the COVID-19 pandemic, the treatment of patients affected with rare kidney disorders became even more challenging. This can be primarily attributed to the fact that the current treatment options for such indications are heavily reliant on regular patient visits to the hospitals or medical centers. Consequently, during the pandemic, a 30% increase in mortality rate was observed in affected patients. This increase in mortality has compelled players engaged in the pharmaceutical domain to undertake necessary research initiatives in order to identify novel drugs that can efficiently treat rare kidney disorders.

Given the complexity associated with conventional treatment options, such as dialysis, kidney transplant and biopsy, drug developers engaged in rare kidney diseases market have shifted their focus towards the development of drugs that can target a myriad of rare kidney disorders. It is worth highlighting that, since 2020, over seven drugs have received marketing approval for the treatment of rare kidney disorders; these are (in reverse chronological order of approval) Galafold® (Fabry disease, European Medicines Agency (EMA), 2021), Lupkynis™ (Lupus Nephritis (LN), United States Food and Drug Administration (USFDA), 2021), Sibnayal™ (distal Renal Tubular Acidosis (dRTA), EMA, 2021), Tarpeyo® (Immunoglobulin A Nephropathy (IgAN), USFDA, 2021), Benlysta® (LN, USFDA, 2020), Cystadrops® (Cystinosis, USFDA, 2020), and Ultomiris® (Atypical Hemolytic Uremic Syndrome (aHUS), Japan, 2020). Further, more than 90 candidates targeting rare kidney disorders are currently under clinical investigation, while several novel leads are being evaluated in early stages of development. Given the lucrative opportunity associated with these targets, rare kidney diseases market has gained attention of both private and public investors in the past few years. In fact, over USD 4.5 billion has been invested in rare kidney diseases market since 2020. As more candidates are likely to progress towards advanced stages of development, we expect the rare kidney diseases market to witness aggressive market growth during the forecast period.

This image highlights the context of Rare Kidney Diseases Market report. Driven by the increased adoption and rising unmet need associated with rare kidney disorders, industry stakeholders have made significant investments to enable the development of novel drug candidates This image provides list of Drugs Targeting Rare Kidney Disorders. Presently, more than 125 drug candidates targeting rare kidney disorders are being investigated across different phases of development This image presents current market landscape of Rare Kidney Disorders Market. About 70% of the drug candidates are currently being evaluated in the clinical stages of development; nearly 50% of the overall pipeline molecules, primarily small molecules, are designed to be delivered via the oral route

Key Drugs in Rare Kidney Diseases Market   

Examples of key drugs developed by companies engaged in rare kidney diseases market (which have also been profiled in this market report; the complete list of drugs is available in the full report) include Atrasentan, Bardoxolone Methyl, Benlysta, Cosentyx®, Cozaar®, Crovalimab, Cystadrops®, Empaveli®, Galafold®, Ianalumab, Iptacopan, Lupkynis™, Narsoplimab, Pegunigalsidase Alfa, Rituxan®, Saphnelo™, Sibnayal™, Sparsentan, Tarpeyo®, Thiola® and Ultomiris®. This market report includes an easily searchable excel database of all the companies and their drugs for treating rare kidney diseases worldwide.

Recent Developments in Rare Kidney Diseases Market

Several recent developments have taken place in the field of rare kidney diseases market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In June 2023, Novartis announced the acquisition of Chinook Therapeutics for the total amount of USD 3.5 billion with an aim to boost its late-stage drug development line-up  for a rare kidney disease treatment.     
  • In May 2023, Chinook Therapeutics entered into a collaboration agreement with Ionis Pharmaceuticals for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy used for the patients suffering from rare, severe chronic kidney disease. 
  • In February 2023, Travere Therapeutics announced the FDA approval of Filspari drug used to treat IgA nephropathy, a rare and deadly autoimmune disease that attacks the kidneys and can lead to organ failure

Scope of the Report

The Rare Kidney Diseases Market - Distribution by Target Indications (IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy and Others), Type of Molecule (Small Molecules and Biologics (Monoclonal Antibody, Hormone, Recombinant Protein, and Others)), Route of Administration (Oral, Intravenous, Subcutaneous, and Others) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecast, 2022-2035 market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities associated with the rare kidney diseases market, over the next decade. The market research report also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in rare kidney diseases market. The below table highlights various market segmentations done in the market research report.

Market Segmentations

Report Attribute Details

Forecast Period

2022 – 2035

Target Indications

Oncological disorders, IgA nephropathy, Lupus nephritis, focal segmental glomerular sclerosis, membranous nephropathy, C3 glomerulopathy, other disorders

Type of Molecule

Small molecules, biologics

Route of Administration

Oral, intravenous, subcutaneous, others
Key Geographical Regions North America, Europe, Asia-Pacific, MENA, Latin America and Rest of the World

 

This image highlights competitive analysis of players engaged in the domain of Rare Kidney Disorders. In order to gain a competitive edge, drug developers are actively undertaking initiatives with an aim to further enhance their respective offerings, both in terms of portfolio strength and diversity This image highlights the partnership activity undertaken by players engaged in Rare Kidney Disorders Market. Industry players are actively forging collaborations with other stakeholders to enable the development of their proprietary drug candidates; ~55% of such deals were inked between firms based in the same region This image provides information on funding and investments made within Rare Kidney Disorders domain. Foreseeing lucrative returns, many investors have disbursed funds worth over USD 3.7 billion in the last few years; 27% of the funding instances in this market were represented by venture capital fundings

Amongst other elements, the market report features:

  • A detailed executive summary of key insights captured during our research. It offers a high-level view on the current state of rare kidney diseases market and its likely evolution in the mid to long term.
  • A brief introduction to various aspects of rare kidney disorders. It includes a detailed discussion on the historical evolution and factors contributing to the treatment of rare kidney disorders. Further, it highlights various prominent target indications associated with rare kidney disorders, application of omics technology and its future perspectives.
  • A detailed overview of the current market landscape of more than 127  drug candidates that are either approved or currently under development for the treatment of various rare kidney disorders, based on several relevant parameters, such as phase of development (approved, registration, phase III, phase II, phase I, pre-clinical and discovery), target molecule (complement component 5 (C5), complement component 3 (C3), a proliferation-inducing ligand (APRIL), B lymphocyte stimulator (BLyS), Complement Factor B, and others), route of administration (oral, intravenous, subcutaneous, and others), and target indication (complement 3 glomerulopathy (C3G), focal segmental glomerular sclerosis (FSGS), IgA nephropathy (IgAN), lupus nephritis (LN), membranous nephropathy (MN)), type of molecule (biologics and small molecules), and type of biologic (monoclonal antibody (mAb), hormone, recombinant protein, enzyme replacement therapy (ERT), gene therapy, small interfering ribonucleic acid (siRNA) molecule and others). In addition, it presents details of the companies engaged in the development of drugs targeting rare kidney disorders, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, and most active players. 
  • Elaborate profiles of approved and clinical stage drugs indicated for rare kidney disorders (phase II / III or above). Each profile features an overview of the drug developer, clinical trial information related to the drug, clinical trial results, and estimated sales revenues (if available).
  • A detailed competitiveness analysis of companies engaged in the development of rare kidney disorders targeting drugs, based on their developer strength (in terms of years of experience), portfolio strength (in terms of number of drugs developed), and portfolio diversity (in terms of phase of development, target indication, and drug designation). 
  • An in-depth analysis of the various collaborations and partnerships that have been inked by players engaged in the development of drugs targeting various rare kidney disorders since 2017, based on several relevant parameters, such as year of partnership, type of partnership, focus area, type of partner and regional distribution of partnerships. 
  • An analysis of the funding and investments made within rare kidney diseases market, during the period 2016-2022, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital financing, debt financing, grants, IPOs and other offerings), leading players (in terms of amount invested) and key investors (in terms of number of funding instances).
  • A detailed clinical trial analysis of ongoing clinical studies for the evaluation of various drug candidates targeting rare kidney disorders, based on several relevant parameters, such as trial registration year, current trial status, phase of development, key target indications, patient age, study design and key geographical regions.  
  • A detailed analysis of the clinical and commercial attractiveness for drugs targeting rare kidney disorders, based on several relevant parameters, such as target patient population, dosing frequency and dose strength.
  • A case study highlighting the companies engaged in offering kidney care services, along with information on their year of establishment, company size (in terms of number of employees), location of headquarters and target indication.

The key objective of rare kidney diseases market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for rare kidney diseases market during the forecast period. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the forecast period 2022-2035. Additionally, the market report features the likely distribution of the current and forecasted opportunity across relevant parameters, such as [A] target indications (complement 3 glomerulopathy (C3G), FSGS, IgAN, LN, membranous nephropathy (MN)), [B] type of molecule (small molecules and biologics (monoclonal antibody, hormone, recombinant protein, and others)),[C] route of administration (oral, intravenous, subcutaneous and others) [D] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World (RoW)). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified. 

This image provides information about completed, ongoing and planned clinical studies of Rare Kidney Disorders. More than 370 clinical trials, with over 39,000 enrolled patients, are currently underway to investigate therapies targeting rare kidney disorders This image provides information about the clinical and commercial attractiveness for drugs targeting rare kidney disorders. In lieu of the growing competition from several viable candidate therapies, innovators are putting in significant efforts to ensure that their proprietary offerings are both clinically and commercially differentiated This image highlights the market segments of Rare Kidney Disorders Market. Given the increase in demand for drugs intended for rare kidney disorders, the overall rare kidney disorders market is poised to grow at a CAGR of over 15% over the next decade

Frequently Asked Questions

Question 1: What are rare kidney diseases?

Answer: Rare kidney diseases include disorders like IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy and C3 Glomerulopathy amongst others. These conditions are primarily genetic, making them difficult to diagnose and treat.

Question 2: What is the projected market growth of the rare kidney diseases market?

Answer: The rare kidney diseases industry is expected to grow at compounded annual growth rate (CAGR) of 15% during the forecast period 2022 - 2035.

Question 3: Which are the leading drugs in the rare kidney diseases market?

Answer: Examples of key drugs developed by companies engaged in rare kidney diseases industry (which have also been profiled in this market report; the complete list of drugs is available in the full report) include Atrasentan, Bardoxolone Methyl, Benlysta, Cosentyx®, Cozaar®, Crovalimab, Cystadrops®, Empaveli®, Galafold®, Ianalumab, Iptacopan, Lupkynis™, Narsoplimab, Pegunigalsidase Alfa, Rituxan®, Saphnelo™, Sibnayal™, Sparsentan, Tarpeyo®, Thiola® and Ultomiris®.

Question 4: How many rare kidney diseases are currently diagnosed globally?

Answer: Globally, around 150 indications are considered as rare kidney diseases.

Question 5: How much investment has been made by key players in the rare kidney diseases market?

Answer: Since 2020, over $4.5 billion has been invested in rare kidney diseases market by key stakeholders.

Question 6: Which geography represents the largest number of patients enrolled in clinical trials related to rare kidney diseases?

Answer: North America encompasses the majority of the patients enrolled in clinical trials related to rare kidney diseases, with nearly 40% of the patients based in this region.

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com